Caroline Ford

Associate Professor

Associate Professor Caroline Ford leads the Gynaecological Cancer Research Group (GCRG) at the University of New South Wales. She established her laboratory at the Lowy Cancer Research Group in 2010 after international postdoctoral fellowships at the University of Toronto, Canada and Lund University, Sweden. She has successfully led her research group for over 11 years maintaining consistent competitive research funding and collaborating closely with clinicians and women with gynaecological cancers.

The Gynaecological Cancer Research Group (GCRG) aims to understand why gynaecological cancers develop, how and why they spread throughout the body, and how best to treat them. “Gynaecological cancer” encompasses all cancers of the female reproductive system, though current research focuses on ovarian and endometrial cancer. The GCRG works closely with clinical staff at the Royal Hospital for Women, Sydney and has a number of studies involving biospecimen collection (tissue, blood and ascites) from women with gynaecological cancer. Major projects include the development of an early detection test for ovarian cancer, and the identification of key targets for anti-metastatic therapies in ovarian and endometrial cancer. The GCRG is also actively investigating biological properties of ovarian cancer-associated ascites, and further developing innovative in vitro organotypic model of ovarian and endometrial cancer for pre-clinical drug testing. They also investigate cell-free DNA and its fluctuation in women, particularly in benign gynaecological diseases including endometriosis.

A/Prof Ford is an experienced university lecturer, convening courses on medical research, cancer pathology and personalised medicine, including Australia's first MOOC (Massive Open Online Course) on Personalised Medicine. She has completed a Graduate Certificate in University Learning & Teaching, and is passionate about science communication and enhancing the health literacy of the wider community. In 2017 she was named as an inaugural ‘Superstar of STEM’ by Science & Technology Australia. In 2018 she received the Women's Agenda Award for Female Leader in Science, Medicine & Health.

Keywords: gynaecological cancer, ovarian cancer, endometrial cancer, endometriosis, metastasis, ascites, early detection, cell-free DNA, Wnt, EMT, ROR1, ROR2, MOOC

Journal articles
add
Alonso A; Yuwono NL; Houshdaran S; Abbott J; Rodgers R; Ford CE; Warton K, 2022, 'Comparison of total and endometrial circulating cell-free DNA in women with and without endometriosis', Reproductive BioMedicine Online, vol. 44, pp. 495 - 503, http://dx.doi.org/10.1016/j.rbmo.2021.11.006
2022
Liu D; Kaufmann GF; Breitmeyer JB; Dickson KA; Marsh DJ; Ford CE, 2022, 'The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells', Pharmaceutics, vol. 14, http://dx.doi.org/10.3390/pharmaceutics14040837
2022
Yuwono NL; Boyd MAA; Henry CE; Werner B; Ford CE; Warton K, 2022, 'Circulating cell-free DNA undergoes significant decline in yield after prolonged storage time in both plasma and purified form', Clinical Chemistry and Laboratory Medicine, http://dx.doi.org/10.1515/cclm-2021-1152
2022
Henry CE; Llamosas E; Djordjevic A; Hacker NF; Ford CE, 2022, 'Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.', Oncogenesis, vol. 11, pp. 32, http://dx.doi.org/10.1038/s41389-022-00408-4
2022
Werner B; Warton K; Ford CE, 2022, 'Transcending Blood—Opportunities for Alternate Liquid Biopsies in Oncology', Cancers, vol. 14, pp. 1309 - 1309, http://dx.doi.org/10.3390/cancers14051309
2022
Liu D; Sharbeen G; Phillips P; Ford CE, 2021, 'ROR1 and ROR2 expression in pancreatic cancer', BMC cancer, vol. 21, pp. 1199, http://dx.doi.org/10.1186/s12885-021-08952-9
2021
Joshi N; Liu D; Dickson KA; Marsh DJ; Ford CE; Stenzel MH, 2021, 'An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles', Journal of Materials Chemistry B, vol. 9, pp. 9123 - 9135, http://dx.doi.org/10.1039/d1tb01837j
2021
Liu D; Enriquez L; Ford CE, 2021, 'Ror2 is epigenetically regulated in endometrial cancer', Cancers, vol. 13, pp. 1 - 16, http://dx.doi.org/10.3390/cancers13030383
2021
Yuwono NL; Henry CE; Ford CE; Warton K, 2021, 'Total and endothelial cell-derived cell-free DNA in blood plasma does not change during menstruation', PLoS ONE, vol. 16, http://dx.doi.org/10.1371/journal.pone.0250561
2021
Hagstrom AD; Yuwono N; Warton K; Ford CE, 2021, 'Sex Bias in Cohorts Included in Sports Medicine Research', Sports Medicine, vol. 51, pp. 1799 - 1804, http://dx.doi.org/10.1007/s40279-020-01405-6
2021
Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C, 2021, 'Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer', Gynecologic Oncology, vol. 162, pp. 720 - 727, http://dx.doi.org/10.1016/j.ygyno.2021.06.028
2021
Yuwono NL; Warton K; Ford CE, 2021, 'The influence of biological and lifestyle factors on circulating cell-free dna in blood plasma', eLife, vol. 10, http://dx.doi.org/10.7554/eLife.69679
2021
Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents', British Journal of Cancer, vol. 125, pp. 265 - 276, http://dx.doi.org/10.1038/s41416-021-01420-y
2021
Liu D; Gunther K; Enriquez LA; Daniels B; O’Mara TA; Tang K; Spurdle AB; Ford CE, 2020, 'ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target', Scientific Reports, vol. 10, pp. 13906, http://dx.doi.org/10.1038/s41598-020-70924-z
2020
Warton K; Xu Y; Ford CE, 2020, 'Target sequence heterogeneity causes the 'hook effect' in fluorescent dye-based quantitative PCR', BioTechniques, vol. 69, pp. 81 - 84, http://dx.doi.org/10.2144/BTN-2020-0016
2020
Ford CE; Werner B; Hacker NF; Warton K, 2020, 'The untapped potential of ascites in ovarian cancer research and treatment', British Journal of Cancer, vol. 123, pp. 9 - 16, http://dx.doi.org/10.1038/s41416-020-0875-x
2020
Werner B; Yuwono NL; Henry C; Gunther K; Rapkins RW; Ford CE; Warton K, 2019, 'Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight', PLoS ONE, vol. 14, pp. e0224338, http://dx.doi.org/10.1371/journal.pone.0224338
2019
Huynh KT; Van Zuylen WJ; Ford CE; Rawlinson WD, 2019, 'Selective modulation of wnt-binding receptor tyrosine kinase ROR2 expression by human cytomegalovirus regulates trophoblast migration', Journal of General Virology, vol. 100, pp. 99 - 104, http://dx.doi.org/10.1099/jgv.0.001179
2019
Lu M; Henry CE; Lai H; Khine YY; Ford CE; Stenzel MH, 2019, 'A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles', Biomaterials Science, vol. 7, pp. 1652 - 1660, http://dx.doi.org/10.1039/c8bm01326h
2019
Cortesi M; Llamosas E; Henry CE; Kumaran RYA; Ng B; Youkhana J; Ford CE, 2018, 'I-AbACUS: A Reliable Software Tool for the Semi-Automatic Analysis of Invasion and Migration Transwell Assays', Scientific Reports, vol. 8, http://dx.doi.org/10.1038/s41598-018-22091-5
2018
Coopes A; Henry CE; Llamosas E; Ford CE, 2018, 'An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target', Endocrine-Related Cancer, vol. 25, pp. R647 - R662, http://dx.doi.org/10.1530/ERC-18-0112
2018
Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE, 2018, 'ROR1 and ROR2 play distinct and opposing roles in endometrial cancer', Gynecologic Oncology, vol. 148, pp. 576 - 584, http://dx.doi.org/10.1016/j.ygyno.2018.01.025
2018
Henry CE; Emmanuel C; Lambie N; Loo C; Kan B; Kennedy CJ; de Fazio A; Hacker NF; Ford CE, 2017, 'Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer', Translational Oncology, vol. 10, pp. 346 - 356, http://dx.doi.org/10.1016/j.tranon.2017.01.014
2017
Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2017, 'Validation of specificity of antibodies for immunohistochemistry: the case of ROR2', Virchows Archiv : an international journal of pathology, vol. 470, pp. 99 - 108, http://dx.doi.org/10.1007/s00428-016-2019-5
2017
Henry C; Hacker N; Ford C, 2017, 'Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis', Oncotarget, vol. 8, pp. 112727 - 112738, http://dx.doi.org/10.18632/oncotarget.22559
2017
Warton K; Yuwono NL; Cowley MJ; McCabe MJ; So A; Ford CE, 2017, 'Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma', Molecular Diagnosis and Therapy, vol. 21, pp. 563 - 570, http://dx.doi.org/10.1007/s40291-017-0284-x
2017
Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2016, 'Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2 (Virchows Archiv, (2016), 10.1007/s00428-016-2019-5)', Virchows Archiv, vol. 469, pp. 717, http://dx.doi.org/10.1007/s00428-016-2036-4
2016
Hesson LB; Ng B; Zarzour P; Srivastava S; Kwok CT; Packham D; Nunez AC; Beck D; Ryan R; Dower A; Ford CE; Pimanda JE; Sloane MA; Hawkins NJ; Bourke MJ; Wong JWH; Ward RL, 2016, 'Integrated genetic, epigenetic, and transcriptional profiling identifies molecular pathways in the development of laterally spreading tumors', Molecular Cancer Research, vol. 14, pp. 1217 - 1228, http://dx.doi.org/10.1158/1541-7786.MCR-16-0175
2016
van Zuylen W; Ford C; Rawlinson W, 2016, 'Comment on: Wnt5a inhibited human trophoblast cell line HTR8/SVneo invasion: implications for early placentation and preeclampsia', The Journal of Maternal-Fetal and Neonatal Medicine, vol. 30, pp. 1085 - 1086, http://dx.doi.org/10.1080/14767058.2016.1203411
2016
Ford CE; Henry C; Llamosas E; Djordjevic A; Hacker N, 2016, 'Wnt signalling in gynaecological cancers: A future target for personalised medicine?', Gynecologic Oncology, vol. 140, pp. 345 - 351, http://dx.doi.org/10.1016/j.ygyno.2015.09.085
2016
Henry C; ford C; hacker N; Djordjevic A; Llamosas E, 2016, 'Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.', Oncogenesis, vol. 5, pp. e226, http://dx.doi.org/10.1038/oncsis.2016.32
2016
vanZuylen WJ; Rawlinson WD; Ford C, 2016, 'The Wnt pathway: a key network in cell signalling dysregulated by viruses.', Reviews in Medical Virology, vol. 26, pp. 340 - 355, http://dx.doi.org/10.1002/rmv.1892.
2016
Ma S; srivastava S; llamosas E; hawkins N; hesson L; ward R; Ford C, 2016, 'ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.', BMC Cancer, vol. 16, http://dx.doi.org/10.1186/s12885-016-2576-7
2016
Naumann F; Yang J-L; Thai T; Ford C; Polly P, 2016, 'Virtual patient consultations and the use of an ePortfolio assessment to support student learning of integrated professional skills', FOCUS ON HEALTH PROFESSIONAL EDUCATION-A MULTIDISCIPLINARY JOURNAL, vol. 17, pp. 69 - 81, http://dx.doi.org/10.11157/fohpe.v17i3.178
2016
van Zuylen WJ; Ford CE; Wong DDY; Rawlinson WD, 2016, 'Human cytomegalovirus modulates expression of noncanonical Wnt receptor ROR2 to alter trophoblast migration', Journal of Virology, vol. 90, pp. 1108 - 1115, http://dx.doi.org/10.1128/JVI.02588-15
2016
Henry C; Llamosas E; Djordjevic A; Hacker N; Ford C, 2016, 'Targeting the RB-E2F pathway in breast cancer', Oncogene, http://dx.doi.org/10.1038/onc.2016.32
2016
Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C, 2015, 'Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion', Oncotarget, vol. 6, pp. 40310 - 40326, http://dx.doi.org/10.18632/oncotarget.5643
2015
Henry CE; Knipprath-Meszaros AM; Llamosas E; Schotzau A; Obermann E; Fink D; Hacker N; Ward RL; Heinzelmann-Schwarz V; Ford CE, 2015, 'ROR2 IS A NOVEL TARGET OF THE WNT SIGNALING PATHWAY INVOLVED IN METASTASIS AND CHEMOTHERAPY RESISTANCE', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 25, pp. 476 - 476, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377145701094&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2015
Henry C; Quadir A; Hawkins NJ; Jary E; Llamosas E; Kumar D; Daniels B; Ward RL; Ford CE, 2015, 'Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling', Journal of Cancer Research and Clinical Oncology, vol. 141, pp. 243 - 254, http://dx.doi.org/10.1007/s00432-014-1824-y
2015
Ford CE; Punnia-Moorthy G; Henry CE; Llamosas E; Nixdorf S; Olivier J; Caduff R; Ward RL; Heinzelmann-Schwarz V, 2014, 'The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer', Gynecologic Oncology, vol. 134, pp. 338 - 345, http://dx.doi.org/10.1016/j.ygyno.2014.06.004
2014
Ford CE; Ma SSQ; Quadir A; Ward RL, 2013, 'The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis', International Journal of Cancer, vol. 133, pp. 779 - 787, http://dx.doi.org/10.1002/ijc.27984
2013
Ford CE; Jary E; Ma SSQ; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL, 2013, 'The WNT gatekeeper SFRP4 modulates EMT, cell migration and downstream WNT signalling in serous ovarian cancer cells', PLoS ONE, vol. 8, pp. e54362, http://dx.doi.org/10.1371/journal.pone.0054362
2013
Loh YN; Hedditch E; Baker L; Jary E; Ward RL; Ford CE, 2013, 'The Wnt signalling pathway is upregulated in acquired Tamoxifen resistant breast cancer.', BMC Cancer, vol. 13, pp. 174, http://dx.doi.org/10.1186/1471-2407-13-174
2013
Ford CE; Jary E; Ma S; Nixdorf S; Heinzelmann-Schwarz V; Ward RL, 2012, 'SFRP4 modulates EMT, cell migration and downstream Wnt signalling in epithelial ovarian cancer.', CANCER RESEARCH, vol. 72, http://dx.doi.org/10.1158/1538-7445.AM2012-333
2012
Jacob F; Ukegjini K; Nixdorf S; Ford CE; Olivier J; Caduff R; Scurry J; Guertler R; Hornung D; Mueller R; Fink D; Hacker NF; Heinzelmann-Schwarz VA, 2012, 'Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients', PLoS One, vol. 7, pp. Art no. e31885, http://dx.doi.org/10.1371/journal.pone.0031885
2012
Johal H; Ford CE; Glenn W; Heads J; Lawson JS; Rawlinson WD, 2011, 'Mouse mammary tumor like virus sequences in breast milk from healthy lactating women', Breast Cancer Research and Treatment, vol. 129, pp. 149 - 155, http://dx.doi.org/10.1007/s10549-011-1421-6
2011
Ford CE; Ekström EJ; Howlin J; Andersson T, 2011, 'The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERα negative breast cancer (Cell Cycle (2009), 8, (1838-1842))', Cell Cycle, vol. 10, pp. 1167, http://dx.doi.org/10.4161/cc.10.7.15488
2011
Ford CE; Ekström EJ; Andersson T, 2010, 'Erratum: Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells (Proceedings of the National Academy of Sciences of the United Stated of America (2010) 106 (3919-3924) DOI: 10.1073/pnas.0809516106))', Proceedings of the National Academy of Sciences of the United States of America, vol. 107, pp. 22360, http://dx.doi.org/10.1073/pnas.1017549108
2010
Ford CE; Ekström EJ; Howlin J; Andersson T, 2009, 'The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERα negative breast cancer', Cell Cycle, vol. 8, pp. 1838 - 1842, http://dx.doi.org/10.4161/cc.8.12.8863
2009
Ford CE; Ekström EJ; Andersson T, 2009, 'Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells', Proceedings of the National Academy of Sciences of the United States of America, vol. 106, pp. 3919 - 3924, http://dx.doi.org/10.1073/pnas.0809516106
2009
Ford CE; Lau S; Zhu CQ; Andersson T; Tsao M; Vogel W, 2007, 'Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.', British Journal of Cancer, vol. 96, pp. 808 - 814, http://dx.doi.org/10.1038/sj.bjc.6603614
2007
Lawson JS; Tran D; Carpenter E; Ford C; Rawlinson WD; Whitaker NJ; Delprado W, 2006, 'Presence of mouse mammary tumour-like virus gene sequences may be associated with morphology of specific human breast cancer', Journal of Clinical Pathology, vol. 59, pp. 1287 - 1292, http://dx.doi.org/10.1136/jcp.2005.035907
2006
Vogel W; Abdulhussein R; Ford CE, 2006, 'Sensing extracellular matrix: An update on discoidin domain receptor function.', Cellular Signalling, vol. 18, pp. 1108 - 1116, http://dx.doi.org/10.1016/j.cellsig.2006.02.012
2006
Pogo B; Menard S; Holland JF; Faedo M; Ford CE; Rawlinson WD, 2005, 'Contribution by Faedo et al. (Clin Cancer Res 2004;10:4417-4419) [1]', Clinical Cancer Research, vol. 11, pp. 406
2005
Faedo M; Ford CE; Mehta R; Blazek K; Rawlinson WD, 2004, 'Mouse mammary tumor like virus is associated with p53 nuclear accumulation and progesterone receptor positivity but not estrogen positivity in human female breast cancer', Clinical Cancer Research, vol. 10, pp. 4417 - 4419, http://dx.doi.org/10.1158/1078-0432.CCR-03-0232
2004
Lawson JS; Tran D; Ford CE; Rawlinson WD, 2004, 'Elevated expression of the tumor suppressing protein p53 is associated with the presence of mouse mammary tumor-like env gene sequences (MMTV-like) in human breast cancer', Breast Cancer Research and Treatment, vol. 87, pp. 13 - 17, http://dx.doi.org/10.1023/B:BREA.0000041573.09142.00
2004
Ford CE; Faedo M; Rawlinson WD, 2004, 'Mouse mammary tumor virus-like RNA transcripts and DNA are found inaffected cells of human breast cancer', Clinical Cancer Research, vol. 10, pp. 7284 - 7289, http://dx.doi.org/10.1158/1078-0432.CCR-04-0767
2004
Ford CE; Faedo M; Delprado W; Rawlinson WD, 2004, 'Correspondence re: C. Ford, et al. Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women.', Clinical Cancer Research, vol. 10, pp. 802 - 802
2004
Ford CE; Faedo M; Lawson JS; Rawlinson WD; Crouch R, 2004, 'Progression from normal breast pathology to breast cancer is associated with increasing prevalence of mouse mammary tumor virus-like sequences in men and women.', Cancer research, vol. 64, pp. 4755 - 4759, http://dx.doi.org/10.1158/0008-5472.CAN-03-3804
2004
Ford CE; Tran D; Deng Y; Ta VT; Rawlinson WD; Lawson JS, 2003, 'Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women', Clinical Cancer Research, vol. 9, pp. 1118 - 1120
2003
Conference Papers
add
Liu D; Kaufmann GF; Breitmeyer JB; Dickson K-A; Marsh DJ; Ford CE, 2021, 'Abstract 1062: Inhibition of ovarian and endometrial cancer cell proliferation by an anti-ROR1 monoclonal antibody', in Cancer Research, American Association for Cancer Research (AACR), pp. 1062 - 1062, presented at Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, http://dx.doi.org/10.1158/1538-7445.am2021-1062
2021
Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Abstract 1045: Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy', in Cancer Research, American Association for Cancer Research (AACR), pp. 1045 - 1045, presented at Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, http://dx.doi.org/10.1158/1538-7445.am2021-1045
2021
Liu D; John M; Henry CE; Christie EL; Bowtell DDL; Tang K; Heinzelmann-Schwarz V; Kennedy C; Boros J; DeFazio A; Ford CE, 2020, 'Abstract A41: ROR1 is associated with ovarian cancer progression and chemoresistance', in Poster Presentations - Proffered Abstracts, American Association for Cancer Research, presented at Abstracts: AACR Special Conference on Advances in Ovarian Cancer Research; September 13-16, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1557-3265.ovca19-a41
2020
Henry CE; Hacker NF; Ford CE, 2018, 'Abstract 106: Shock and ROR! Targeting ROR1 and ROR2 in a preclinical patient-derived model of ovarian cancer', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL, http://dx.doi.org/10.1158/1538-7445.am2018-106
2018
Henry CE; Llamosas E; Hacker NF; Heinzelmann-Schwarz V; Ford CE, 2016, 'The role of the ROR receptors in ovarian cancer progression and chemoresistance', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, New Orleans, LA, presented at 107th Annual Meeting of the American-Association-of-Cancer-Research (AACR), New Orleans, LA, 16 April 2016 - 20 April 2016, http://dx.doi.org/10.1158/1538-7445.AM2016-1636
2016
Ford CE; Tuomela J; Hedditch EL; Axelsson L; Liu Q; Ward RL; Harkonen P; Andersson T, 2010, 'Estrogen receptor alpha is upregulated and metastasis inhibited in a murine breast cancer model following treatment with the novel Wnt-5a derived-hexapeptide, Foxy-5', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Oslo, NORWAY, pp. 11 - 11, presented at 21st Meeting of the European-Association-for-Cancer-Research, Oslo, NORWAY, 26 June 2010 - 29 June 2010, http://dx.doi.org/10.1016/S1359-6349(10)70852-1
2010
Kennedy S; Waliuzzaman Z; Ford C; Rawlinson W; Pussell B, 2005, 'Recurrent HUS following kidney transplant possibly precipitated by CMV', in IMMUNOLOGY AND CELL BIOLOGY, BLACKWELL PUBLISHING, Canberra, AUSTRALIA, pp. A16 - A17, presented at 23rd Annual Scientific Meeting of the Transplantation-Society-of-Australia-and-New-Zealand, Canberra, AUSTRALIA, 11 May 2005 - 13 May 2005, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230636500066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2005
Preprints
add
John M; Rao P; Noor H; Ford C, 2021, ROR1 is a novel putative druggable target for diffuse glioma, http://dx.doi.org/10.1101/2021.12.03.21267166
2021
John M; Ford C, 2021, Pan-tissue and -cancer analysis of ROR1 and ROR2 transcript variants identify novel functional significance for an alternative splice variant of ROR1, http://dx.doi.org/10.1101/2021.11.24.469652
2021
Conference Presentations
add
Ford C; Chisholm O; Gomes L, 2016, 'The Hope and Hype of the Genetic Revolution: Reflections on UNSW Medicine's First MOOC', presented at Connections Seminar Series, UNSW Australia, UNSW Australia, 19 May 2016 - 19 May 2016
2016
Nixdorf S; Chisholm OT; Gomes L; Ford C, 2016, 'Student Engagement in the Personalised Medicine MOOC: Does the Learning Platform Matter?', presented at UNSW Medicine Learning and Teaching Forum, UNSW, Sydney, 07 December 2016 - 07 December 2016
2016
Ford C; Chisholm OT; Gomes L, 2015, 'Hope and Hype: Reflections on UNSW Medicine's First MOOC', presented at 2015 UNSW Medicine Learning and Teaching Forum, UNSW, Sydney, NSW, Australia, 02 December 2015 - 02 December 2015, https://med.unsw.edu.au/annual-learning-and-teaching-forum
2015
Ford C, 2014, 'Hear the Ror! The role of Wnt signalling in ovarian cancer.', presented at International Society for Gynecologic Cancers, Melbourne, 08 November 2014 - 11 April 2015
2014
Chisholm O; Nixdorf S; Williams R; Ford C, 2014, 'Reflections on the development of an open online course', presented at UNSW Medicine Learning and Teaching Forum 2014, UNSW Australia, 10 December 2014 - 10 December 2014, http://med.unsw.edu.au/annual-learning-and-teaching-forum
2014
Ford CE; Henry CE; Llamosas E; Djordjevic A; Hacker NF; Heinzelmann-Schwarz VA; Ward RL, 2014, 'HEAR THE ROR! THE ROLE OF WNT SIGNALLING IN OVARIAN CANCER', Vol. 24, pp. 952 - 952, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966501261&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Conference Posters
add
Chisholm OT; Gomes L; Thai T; Nixdorf S; Williams R; Clayphan A; Vigentini L; Zhang C; Zhao L; King M; Ford C, (ed.), 2016, 'Empowering Online Learners Using Assessment and Feedback', UNSW, presented at Towards 2025: Inspiring Learning, UNSW, 31 October 2016 - 31 October 2016
2016

Cancer Cell Biology, Cancer and Related Disorders, Women's Health

Ford C; Chisholm O, 2015, Brace yourself genetic testing might give you more than you bargained for., https://theconversation.com/brace-yourself-genetic-testing-might-give-you-more-than-you-bargained-for-40246
2015

Dr Ford developed and currently convenes the UNSW General Education course, Personalised Medicine (GENM0295).

Dr Ford developed and convened the Myths and Realities of Personalised Medicine MOOC (Massive Open Online Course) previously offered on the Coursera and Future Learn platforms in 2016 and 2017.